Holderried, Tobias A. W. 
; Fraccaroli, Alessia ; Schumacher, Martin ; Heine, Annkristin ; Brossart, Peter ; Stelljes, Matthias ; Klobuch, Sebastian ; Kröger, Nicolaus ; Apostolova, Petya ; Finke, Jürgen ; Zeiser, Robert ; Heinicke, Thomas ; Bornhäuser, Martin ; von Bergwelt-Baildon, Michael ; Tischer, Johanna ; Wolf, Dominik
; Fraccaroli, Alessia ; Schumacher, Martin ; Heine, Annkristin ; Brossart, Peter ; Stelljes, Matthias ; Klobuch, Sebastian ; Kröger, Nicolaus ; Apostolova, Petya ; Finke, Jürgen ; Zeiser, Robert ; Heinicke, Thomas ; Bornhäuser, Martin ; von Bergwelt-Baildon, Michael ; Tischer, Johanna ; Wolf, Dominik 
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant high-risk hematological diseases. The Graft-vs.-Tumor (GvT) effect is the major hallmark of this treatment approach. However, disease relapse remains a major limitation. Boosting the GvT effect by checkpoint inhibitors (CI) is an attractive option in this desperate situation ...
Owner only: item control page
Altmetric